| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comparison of the quality of informed consent for phase I oncology trials over a 30-year period
|
Malik, Laeeq
|
|
2018
|
82 |
5 |
p. 907-910
|
artikel
|
| 2 |
A new non-dilution rapid desensitization protocol successfully applied to all-grade platinum hypersensitivity
|
Chung, Soo Jie
|
|
2018
|
82 |
5 |
p. 777-785
|
artikel
|
| 3 |
A novel TRAIL mutant-TRAIL-Mu3 enhances the antitumor effects by the increased affinity and the up-expression of DR5 in pancreatic cancer
|
Huang, Min
|
|
2018
|
82 |
5 |
p. 829-838
|
artikel
|
| 4 |
A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement
|
Fountzilas, Elena
|
|
2018
|
82 |
5 |
p. 877-885
|
artikel
|
| 5 |
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
|
O’Brien, Mary E. R.
|
|
2018
|
82 |
5 |
p. 757-766
|
artikel
|
| 6 |
A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjects
|
Hanes, Vladimir
|
|
2018
|
82 |
5 |
p. 899-905
|
artikel
|
| 7 |
Biotransformation of [14C]-ixazomib in patients with advanced solid tumors: characterization of metabolite profiles in plasma, urine, and feces
|
Pusalkar, Sandeepraj
|
|
2018
|
82 |
5 |
p. 803-814
|
artikel
|
| 8 |
Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma
|
Iida-Ueno, Ayako
|
|
|
82 |
5 |
p. 857-864
|
artikel
|
| 9 |
Changes in plasma interleukin-8 and tumor necrosis factor-α levels during the early treatment period as a predictor of the response to sorafenib in patients with unresectable hepatocellular carcinoma
|
Iida-Ueno, Ayako
|
|
2018
|
82 |
5 |
p. 857-864
|
artikel
|
| 10 |
Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy
|
Farshchian, Negin
|
|
2018
|
82 |
5 |
p. 787-793
|
artikel
|
| 11 |
Correction to: An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models
|
Banerji, Udai
|
|
2018
|
82 |
5 |
p. 911-912
|
artikel
|
| 12 |
Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment
|
Tao, Kelong
|
|
2018
|
82 |
5 |
p. 815-827
|
artikel
|
| 13 |
Effect of cyclosporine coadministration on the pharmacokinetics of eltrombopag in healthy volunteers
|
Aslanis, Vassilios
|
|
2018
|
82 |
5 |
p. 847-855
|
artikel
|
| 14 |
Feasibility of 5-fluorouracil pharmacokinetic monitoring using the My-5FU PCM™ system in a quaternary oncology centre
|
Moloney, Michael
|
|
2018
|
82 |
5 |
p. 865-876
|
artikel
|
| 15 |
Gender differences in doxorubicin pharmacology for subjects with chemosensitive cancers of young adulthood
|
Liu, Z.
|
|
2018
|
82 |
5 |
p. 887-898
|
artikel
|
| 16 |
In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia
|
Qosa, Hisham
|
|
2018
|
82 |
5 |
p. 795-802
|
artikel
|
| 17 |
Liposomal therapies in oncology: does one size fit all?
|
Sousa, Isabel
|
|
|
82 |
5 |
p. 741-755
|
artikel
|
| 18 |
Liposomal therapies in oncology: does one size fit all?
|
Sousa, Isabel
|
|
2018
|
82 |
5 |
p. 741-755
|
artikel
|
| 19 |
Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
|
Satake, Hironaga
|
|
2018
|
82 |
5 |
p. 839-845
|
artikel
|
| 20 |
Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer
|
Messaritakis, Ippokratis
|
|
2018
|
82 |
5 |
p. 767-775
|
artikel
|
Tijdschrift beschrijving